Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes—a Pediatric Nephrology Research Consortium study

Overview of attention for article published in Pediatric Nephrology, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 24 X users

facebook: 1 Facebook page

Readers on

mendeley: 66 Mendeley

So far, Altmetric has seen 30 X posts from 24 X users, with an upper bound of 61,253 followers.

@kidney_boy @UNCKidney @MuffLuett https://t.co/Vw1ut2gPDW #NephJC

RT @Ped_Neph: Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS). This Pediatric Nephrology Research Con…

Eculizumab has been used broadly including off-label indications (44%) across 21 centers. Greatest renal function benefit in HUS related disease, and improvement in proteinuria in GN disease. Few adverse events reported. Dr. Cheryl Tran #MayoClinicKidne…

RT @Ped_Neph: Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS). This Pediatric Nephrology Research Con…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 26 additional X posts.